The latest announcement is out from Firebrick Pharma Limited ( (AU:FRE) ).
Firebrick Pharma Limited has secured a $1.1 million strategic investment from Pharma Nutria N.A., Inc., a partner associated with its licensing partner in the Philippines. This investment will support the marketing of Nasodine Nasal Spray in Singapore, new product development, and other operational costs, highlighting the strong partnership and confidence in Firebrick’s growth potential and innovative products.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company is currently marketing Nasodine Nasal Spray and has introduced it in the United States, Singapore, Fiji, and the South Pacific, with plans to launch in the Philippines.
YTD Price Performance: 45.16%
Average Trading Volume: 156,775
Technical Sentiment Consensus Rating: Sell
Learn more about FRE stock on TipRanks’ Stock Analysis page.